FDA Approves Crizotinib for Treatment of ALK+ Inflammatory Advanced Myofibroblastic Tumors

Article

Patients with ALK-positive inflammatory myofibroblastic tumors can now receive treatment with crizotinib following the agent’s approval by the FDA.

Crizotinib (Xalkori) has received approval from the FDA for the treatment of patients with unresectable, recurrent, or refractory ALK-positive inflammatory myofibroblastic tumors who are 1 year of age or older, according to a press release from the FDA.

The agent was evaluated in multiple clinical trials, including the phase 1/2 ADVL912 trial (NCT00939770) in a younger population of patients with relapsed/refractory solid tumors or anaplastic large cell lymphoma (n = 14), as well as the phase 1 A8081013 trial (NCT01121588) in adult patients solid ALK-positive malignancies with the exception of non–small cell lung cancer (n = 7). The oral drug can be administered at a recommended dose of 250 mg twice daily in adults and 280 mg/m2 twice daily in pediatric patients until progression or unacceptable toxicity.

The overall response rate was 86% (95% CI, 57%-98%) in the ADVL912 trial, with 5 of 7 patients in the A8081013 trial experiencing objective responses. Common adverse effects (AEs) in the pediatric population included vomiting, nausea, diarrhea, abdominal pain, rash, vision disorder, upper respiratory tract infection, cough, pyrexia, musculoskeletal pain, fatigue, edema, constipation, and headache, with common AEs in the adult population consisting of vision disorders, nausea, and edema.

Reference

FDA approves crizotinib for ALK-positive inflammatory myofibroblastic tumor. News release. FDA. July 14, 2022. Accessed July 14, 2022. https://bit.ly/3o10Eij

Related Videos
Cancer vaccines are a “cross-cutting approach” that may be applicable across several cancer types, according to Catherine J. Wu, MD.
mRNA may be a potential modality for developing cancer-based vaccines, according to Catherine J. Wu, MD.
Analyzing the KRAS mutation across various cancer types may be a worthwhile target when using a cancer vaccine or immunotherapy, says Catherine J. Wu, MD.
The AACR Health Disparities Report highlights the changes needed to achieve health equity for patients with cancer.
Robert A. Winn, MD, gives insight into how institutions and community practices can improve access to cancer care.
In the October edition of Snap Recap, we review the latest FDA news and the vote from the last ODAC meeting.
In this September edition of Snap Recap, we share our highlights from Prostate Cancer Awareness Month, news in the breast cancer space, and the latest FDA updates.
Implementing tax benefits for manufacturers who produce chemotherapy drugs may be one solution to increase drug production in the United States, according to Lucio N. Gordan, MD.
Lucio N. Gordan, MD, describes how his practice deals with increasing costs of limited chemotherapy agents to ensure that patients with cancer continue to receive treatment.